Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
RUA Life Sciences PLC - holding company of multiple medical device businesses - Pretax loss narrows to just £10,000 in the financial year to March 31 from £2.0 million a year prior. Revenue jumps to £4.1 million from £2.2 million although administrative expenses rise to £4.2 million from £3.8 million. All revenue-generating business units contribute to the growth, with Biomaterials growing 18% from £496,000 to £587,000, and the Medical Device and Components business more than doubling to £3.5 million from £1.7 million. Gross margin fell from 81% to 77% partly due to the Biomaterials business, on which gross margins remain at over 94%, being diluted by the faster-growing contract manufacturing business. ‘Compared to other industries, growing a medical device business can be frustratingly slow due to the necessary regulatory requirements; however, the past 12 months have been exceptional, with a doubling in the scale of the business. The new business opportunities being pursued are equally exciting and, if successful, will add further to the growing high-quality revenues,’ says Chair Geoff Berg.
Current stock price: 12.94 pence, closed down 1.4% in London on Wednesday
12-month changed: up 18%
Copyright 2025 Alliance News Ltd. All Rights Reserved.